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The enantioselective biotransformation of propranolol (Prop) by the endophytic fungi Phomopsis sp., Glomerella cingulata, 
Penicillium crustosum, Chaetomium globosum and Aspergillus fumigatus was investigated by studying the kinetics of the aromatic 
hydroxylation reaction with the formation of 4-hydroxypropranolol (4-OH-Prop). Both Prop enantiomers were consumed by the 
fungi in the biotransformation process, but the 4-hydroxylation reaction yielded preferentially (-)-(S)-4-OH-Prop. The quantity of 
metabolites biosynthesized varied slightly among the evaluated endophytic fungi. These results show that all investigated endophytic 
fungi could be used as biosynthetic tools in biotransformation processes to obtain the enantiomers of 4-OH-Prop. 
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INTRODUCTION
In humans, cytochrome P450 is a superfamily of heme-containing 
enzymes that perform a great variety of reactions on a wide range of 
substrates, including pharmaceuticals.1 Some metabolites produced 
in the biotransformation reactions are biologically active themselves, 
and the study of their effects is crucial in evaluating drug’s efficacy, 
toxicity, and pharmacokinetics.2 These studies, however, require 
large quantities of the pure metabolites, and in some cases, they may 
be difficult to synthesize. An alternative to chemical synthesis is to 
use biomimetic systems that reproduce the action of the P450s to 
generate the metabolites of the drugs or the drug candidates. Isolated 
enzymes or microorganisms (fungi, bacteria or yeasts) can be used 
in biotransformation processes to generate specific metabolites.3
Among the sources for microbial biotransformations, fungi seem 
to be promising due to the possibility of obtaining large quantities 
of the major and the minor metabolites. In addition, the use of these 
microorganisms has the advantages of biotransformation with lower 
cost, greater efficiency and in less time when compared to other 
biotransformation processes, such as with the use of experimental ani-
mals, mammalian enzyme systems or cell cultures.4 In addition, fungi 
can perform regio- and enantio-selective reactions,5 allowing to obtain 
a particular specie without the need of a laborious purification step.
Endophytic fungi is a term applied to those fungi that live 
within plant tissues, for all or part of their life cycle, and cause no 
apparent infections.6 Endophyte-host relationships are remarkable 
for the expression of a balance of antagonisms between endophytic 
virulence and plant defensive response.7 In recent years, the number 
of works that use endophytic fungi in biotransformation processes 
has also increased.8
Non selective b-adrenergic blockers are therapeutic agents that 
inhibit the effect of catecholamines on b1- and b2-adrenergic recep-
tors. One example of a common b-adrenergic blocker is propranolol 
(Prop), which has been prescribed to treat hypertension, tachyarrhyth-
mia, angina pectoris, myocardial infarction and others.9 Prop is an 
aryl-substituted alkylamine, containing a naphthalene moiety which 
comprises its fluorophore and an alkyl side chain which has one chi-
ral center. The b-blocking activity of (-)-(S)-Prop is about 100 times 
higher than the activity observed for (+)-(R)-Prop.10 The main meta-
bolite 4-hydroxypropranolol (4-OH-Prop) is also pharmacologically 
active (see Figure 1 compound structures).11 Since (–)-(S)-OH-Prop 
is also pharmacologically active, it would be interesting to obtain this 
active metabolite by a biotransformation process. 
The microbial biotransformation of Prop was previously studied 
by Foster et al..12 The fungus Cunninghamella bainieri biotransformed 
Prop to 4-OH-Prop and the metabolites desisopropylpropranolol, 
propranolol glycol, 1-naphthoxylactic acid and 1-naphthoxyacetic 
acid were also found in trace amounts. C. echinulata was also used to 
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Figure 1. Chemical structures of propranolol and 4-hydroxypropranolol 
enantiomers. *Chiral center
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biotransform Prop,13 but the observed profile was different because the 
major metabolite formed was identified as 8-hydroxypropranolol. In 
addition, the authors reported an enantioselective biotransformation by 
the fungus, which initially metabolized (–)-(S)-Prop in a faster way and 
to a greater extention to 8-hydroxypropranolol than to (+)-(R)-Prop.
Based on these concerns, Prop was selected as a model analyte to 
study the aromatic hydroxylation reaction by some endophytic fungi. 
The reaction was followed by using an enantioselective method, the-
refore, the enantioselectivity of the process of Prop biotransformation 
to its active metabolite 4-hydroxypropranolol could be evaluated.
EXPERIMENTAL
Microorganisms
The endophytic fungi have been isolated and identified by their 
rDNA sequences as previously described.14 The selected strains were 
Phomopsis sp. (TD2) isolated from Tithonia diversifolia; Glome-
rella cingulata (VA1) isolated from Viguiera arenaria; Penicillium 
crustosum (VR4), Chaetomium globosum (VR10) and Aspergillus 
fumigatus (VR12) isolated from Viguiera robusta. The fungi have 
been deposited in the Academic Laboratory of Chemistry of Micro-
organisms of Faculty of Pharmaceutical Sciences of Ribeirão Preto 
(University de São Paulo, Ribeirão Preto, Brazil) and have been 
maintained as agar plugs in sterile water, in silica gel (6 to 12 mesh, 
grade 40, desiccant activated) at 10 oC, or on potato dextrose agar 
(PDA) slants and stored at 4 oC.
Chemicals
Rac-propranolol (99%) was obtained from Sigma Aldrich (St. 
Louis, USA) and rac-4-hydroxypropranolol (98%) was obtained from 
Toronto Research Chemicals (North York, Canada). Carboxymethyl-
b-cyclodextrin (CM-b-CD) was obtained from Fluka (Buchs, Swit-
zerland). Acetaminophen (Acet, 98%) obtained from Sigma Aldrich 
(St. Louis, USA) was used as internal standard on the analytical 
procedure. Triethylamine (TEA) was purchased from J.T. Baker 
(Phillipsburg, USA) and phosphoric acid (H3PO4, 85% in water) 
was obtained from Labsynth (Diadema, Brazil). Sodium hydroxide 
was purchased from Nuclear (Diadema, Brazil). Diethyl ether was 
purchased from Mallinckrodt Baker (Paris, USA) and ethyl acetate 
from Tedia (Fairfield, USA). All other chemicals were of analytical-
grade in the highest purity available. Water was distilled and purified 
using a Millipore Milli-Q Plus system (Bedford, USA).
Biotransformation conditions
Step I
Three discs of 0.5 cm of diameter containing the fungal mycelia 
were aseptically transferred to 9.0 cm diameter Petri dishes containing 
PDA and allowed to grow for 7 days at 25 oC.
Step II
Three uniform discs of 0.5 cm diameter of each endophytic fun-
gus mycelia studied were cut with a transfer tube (Fischer Scientific, 
Pittsburgh, USA) and then inoculated in 50 mL Falcon tubes contai-
ning 10 mL of pre-fermentative medium (10.0 g malt extract, 10.0 
g dextrose, 5.0 g triptone and 3.0 g yeast extract and distilled water 
to 1 L and pH adjusted to 6.2 ± 0.2 with a solution of 0.5 mol L-1 
HCl) that was used for the appropriate growth of the microorganism.
Step III
The mycelium obtained after three days was completely trans-
ferred to 250 mL Erlenmeyer flask containing 100 mL of modified 
Czapek medium (25.0 g sucrose, 2.0 g NaNO3, 1.0 g KH2PO4, 0.5 
g MgSO4.7H2O, 0.5 g KCl, 0.01 g FeSO4.7H2O, and distilled water 
to 1.0 L, pH adjusted to 5.0 with a solution of 1.0 mol L-1 HCl). 
At this point, rac-Prop (2 mg) was dissolved in 100 mL of N,N-
dimethylformamide and added to modified Czapek medium. This 
solution was filter-sterilized with a disposable 0.22 µm membrane 
filter (Millipore, São Paulo, Brazil) and the exact concentration of 
Prop was determined using the CE method. The quantification of 
Prop was necessary due to the drug loss by adsorption onto the filter 
matrix. The cultures were incubated for 144 h at 30 oC, in the dark-
ness, with shaking at 120 rpm.
Enantioselective capillary electrophoretic method
The analytical method used for the determination of Prop and 
4-OH-Prop enantiomers by capillary electrophoresis was previously 
described by our group.8 In summary, the analytes were extracted from 
the culture medium using a mixture of diethyl ether: ethyl acetate 
(1:1, v/v) and the analyses were performed on an Agilent Technolo-
gies CE system (Waldbronn, Germany) model G1600A, consisting 
of an analyzer, an automatic sampler and a diode array detector. A 
fused-silica uncoated capillary obtained from MicroSolv Technology 
Corporation (Eatontown, USA) of 50 µm id, 50.0 cm in total length, 
and 41.5 cm in effective length was used. The electrophoretic condi-
tions were: 4% (w/v) CM-b-CD in 25 mmol L-1 TEA/H3PO4 buffer 
at pH 9 as running electrolyte and 17 kV of voltage. UV detection 
was carried out at 208 nm. Sample injections were performed hy-
drodynamically at a pressure of 50 mbar for 20s and the capillary 
temperature was set at 25 oC. 
Calibration curves were obtained by spiking aliquots of 1 mL 
liquid Czapek medium with standard solutions of rac-Prop and 
rac-4-OH-Prop to obtain enantiomer concentrations in the range of 
0.10–10.0 and 0.25–10.0 µg mL-1, respectively. The internal standard 
(acetaminophen) was used in the concentration of 100 µg mL-1. 
RESULTS AND DISCUSSION
The use of microbial models to study the biotransformation of 
drugs have several advantages over studies with animals and humans, 
due to lower cost, ease of setup and manipulation, and higher yield and 
diversity of metabolite production. Microbial metabolite production 
is especially important for metabolites that are hardly synthesized 
by organic chemical methods. An important goal in microbial model 
studies is to develop a list of microorganisms that can mimic the 
metabolic profiles of drugs in mammals.
In our previous work reporting the development and validation 
of the enantioselective method for the analysis of Prop and 4-OH-
Prop in culture medium, we also showed the results obtained for the 
biotransformation reaction after 3 days of incubation.8 In the present 
paper, we are presenting the kinetic study of Prop biotransformation 
by some endophytic fungi. This investigation permitted to monitor the 
obtained metabolite concentrations versus time and the formation and 
consumption of formed metabolites. In addition, we could observe 
the formation of other metabolic species that were not monitored.
All endophytic fungi studied were able to enantioselectively bio-
transform Prop to 4-OH-Prop, the active metabolite. The percentage of 
metabolites produced was calculated considering the Prop amount (2 
mg) that was added in 100 mL of culture medium (20 µg mL−1), which 
resulted in concentrations of 10 µg mL−1 of each enantiomer, (+)-(R)-
Prop and (–)-(S)-Prop. Generally, the concentrations of 4-OH-Prop 
enantiomers increased during the first 3 days and then they began to 
decrease slowly for the next 4 days, since these metabolites had also 
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started to be consumed and transformed to other products, as seen 
in the biotransformation process employing Phomopsis sp. (TD2). 
Figure 2 shows the typical electropherograms obtained from samples 
of the investigated biotransformation process. Noninoculated controls 
and cultures with Prop absence did not present peaks corresponding 
neither to any of the enantiomers nor to other unknown compounds.
Phomopsis sp. (TD2) was able to biotransform (–)-(S)- and 
(+)-(R)-Prop; 45 % of (–)-(S)- Prop added to the reaction medium 
was transformed to (–)-(S)-4-OH-Prop in 72 h, whereas only 12% 
of (+)-(R)-Prop was converted to (+)-(R)-4-OH-Prop in this period 
of incubation (Figure 3a). The enantioselectivity in the production 
of the metabolite was lost in longer analysis time. In addition, other 
unidentified metabolites were also observed for this fungus. So, Pho-
mopsis sp. (TD2) is a fungus that deserves more studies using higher 
amounts of substrate (Prop) for the isolation and characterization of 
the unknown metabolites (A and B, Figure 2).
Glomerella cingulata (VA1) biotransformed 29.1% and 47.7% 
of (–)-(S)-Prop to (–)-(S)-4-OH-Prop within 24 and 72 h of incuba-
tion, respectively (Figure 3b). The (+)-(R)-4-OH-Prop metabolite 
had not been formed before 72 h of incubation, showing that this 
fungus is very interesting for the production of the active enantio-
mer of the metabolite. The highest concentration (0.83 µg mL-1) of 
(+)-(R)-4-OH-Prop metabolite was observed in 120 h of incubation 
(Figure 3b).
The other three fungi, Penicillium crustosum (VR4), Chaetomium 
globosum (VR10) and Aspergillus fumigatus (VR12) showed similar 
metabolic profile (Figure 3 c-d), except for longer incubation periods. 
In this case, both Chaetomium globosum (VR10) and Aspergillus 
fumigatus (VR12) showed higher enantioselectivitiy in the produc-
tion of the metabolite (–)-(S) after 144 h of incubation. In 48 h of 
incubation, Chaetomium globosum (VR10) presented the formation 
of 24.1% of (-)-(S)-4-OH-Prop and it did not form (+)-(R)-4-OH-
Prop (Figure 3d). With longer periods of incubation with Aspergillus 
fumigatus (VR12), it was evidenced higher enantioselectivity for the 
formation of (-)-(S)-4-OH-Prop. In general, 38.3 to 45.1% of (–)-(S)-
Prop were transformed to (–)-(S)-4-OH-Prop, and 23.1 to 29.8 % of 
(+)-(R)-Prop were transformed to (+)-(R)-4-OH-Prop.
In humans, CYP2D6 and CYP1A2 are the major P450s respon-
sible for the biotransformation of Prop15 to the different products. 
Figure 2. Electropherograms of some endophytic fungi studied: Glomerella 
cingulata (VA1) after 144 h of incubation, Chaetomium globosum (VR10) 
after 144 h of incubation and Phomopsis sp. after 72 h of incubation (TD2), 
(1) Acet, (2) (-)-(S)-4-OH-Prop, (3) (+)-(R)-4-OH-Prop, (4) (-)-(S)-Prop and 
(5) (+)-(R)-Prop. Electrophoretic conditions: buffer concentration of 25 mmol 
L-1, buffer pH 9, 4% (w/v) of CM-b-CD and voltage of 17 kV
Figure 3. Concentration–time profile of PROP and 4-OH-PROP enantiomers 
in modified Czapek medium with (a) Phomopsis sp. (TD2); (b) Glomerella 
cingulata (VA1); (c) Penicillium crustosum (VR4), (d) Chaetomium globosum 
(VR10), and (e) Aspergillus fumigatus (VR12)
The ring-hydroxylated products (4-OH-Prop and 5-OH-Prop) are of 
particular importance due to their pharmacological activities.16 The 
study of these microorganisms in semi-preparative or preparative 
scale can be useful to isolate the metabolites from culture medium 
in bigger amounts. 
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Finally, as a suitable alternative to Cunninghamella species, 
the endophytic fungi could be used as complementary models for 
predicting in vivo metabolism and to produce metabolites of drugs, 
that could be used for bionalytical method development and other 
applications.
CONCLUSIONS
The results obtained here show that the used endophytic fungi 
biotransformed Prop trough 4-hydroxylation, as it happens in mam-
mals. In addition, the 4-hydroxilation occurred preferentially with the 
formation of the S-enantiomer, the more active metabolite. Endophytic 
fungi have proven to be a valuable tool to predict in vivo metabolism 
and to produce quantities of metabolites to be used as reference stan-
dard for bionalytical method development and for other applications.
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